1-3 of 3
Nicholas Chiorazzi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model

Available to Purchase
Shih-Shih Chen, Jacqueline C. Barrientos, Gerardo Ferrer, Morgan King-Richards, Yu-Ju Chen, Priyadarshini Ravichandran, Michael Ibrahim, Yasmine Kieso, Sheila Waters, Jeffery L. Kutok, Marisa Peluso, Sujata Sharma, David T. Weaver, Jonathan A. Pachter, Kanti R. Rai, Nicholas Chiorazzi
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (10): 1984–1995.
https://doi.org/10.1158/1078-0432.CCR-22-2386
Published: 15 May 2023
View articletitled, Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model
Open the PDF for Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model in another window
Includes: Supplementary data
Journal Articles

Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model

Free
Carsten U. Niemann, Helena I. Mora-Jensen, Eman L. Dadashian, Fanny Krantz, Todd Covey, Shih-Shih Chen, Nicholas Chiorazzi, Raquel Izumi, Roger Ulrich, Brian J. Lannutti, Adrian Wiestner, Sarah E.M. Herman
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (19): 5814–5823.
https://doi.org/10.1158/1078-0432.CCR-17-0650
Published: 01 October 2017
View articletitled, Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model
Open the PDF for Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model in another window
Includes: Supplementary data
Journal Articles

Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes

Free
Aliki Xochelli, Panagiotis Baliakas, Ioannis Kavakiotis, Andreas Agathangelidis, Lesley-Ann Sutton, Eva Minga, Stavroula Ntoufa, Eugen Tausch, Xiao-Jie Yan, Tait Shanafelt, Karla Plevova, Myriam Boudjogra, Davide Rossi, Zadie Davis, Alba Navarro, Yorick Sandberg, Fie Juhl Vojdeman, Lydia Scarfo, Niki Stavroyianni, Andrey Sudarikov, Silvio Veronese, Tatiana Tzenou, Teodora Karan-Djurasevic, Mark Catherwood, Dirk Kienle, Maria Chatzouli, Monica Facco, Jasmin Bahlo, Christiane Pott, Lone Bredo Pedersen, Larry Mansouri, Karin E. Smedby, Charles C. Chu, Véronique Giudicelli, Marie-Paule Lefranc, Panagiotis Panagiotidis, Gunnar Juliusson, Achilles Anagnostopoulos, Ioannis Vlahavas, Darko Antic, Livio Trentin, Marco Montillo, Carsten Niemann, Hartmut Döhner, Anton W. Langerak, Sarka Pospisilova, Michael Hallek, Elias Campo, Nicholas Chiorazzi, Nikos Maglaveras, David Oscier, Gianluca Gaidano, Diane F. Jelinek, Stephan Stilgenbauer, Ioanna Chouvarda, Nikos Darzentas, Chrysoula Belessi, Frederic Davi, Anastasia Hadzidimitriou, Richard Rosenquist, Paolo Ghia, Kostas Stamatopoulos
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (17): 5292–5301.
https://doi.org/10.1158/1078-0432.CCR-16-3100
Published: 31 August 2017
View articletitled, Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
Open the PDF for Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes in another window
Includes: Supplementary data